1. Clinical and genetic predictions of early-onset cardiac toxicity in adjuvant chemotherapy for breast cancer.
- Author
-
Liu B, Guan X, Wang Y, Sun X, Yi Z, Lv D, Wang W, Li L, Zhai J, Li H, and Ma F
- Subjects
- Anthracyclines adverse effects, Chemotherapy, Adjuvant adverse effects, Female, Humans, Natriuretic Peptide, Brain therapeutic use, Stroke Volume, Breast Neoplasms drug therapy, Breast Neoplasms genetics, Cardiotoxicity etiology, Cardiotoxicity genetics
- Abstract
Aim: To identify clinical and genetic variants associated with early-onset cardiac toxicity with a low cumulative dose of chemotherapy drugs in breast cancer. Methods: A total of 388 recruited patients completed routine blood, liver and kidney function, D-dimer, troponin T, brain natriuretic peptide (BNP) or N-terminal prohormone of BNP, ECG and echocardiography tests before and after adjuvant chemotherapy. 25 single-nucleotide polymorphisms (SNPs) were tested. Results: A total of 277 adjuvant chemotherapy-related cardiac toxicity events were recorded in 180 patients (46.4%). Anthracycline-containing chemotherapy (odds ratio: 1.848; 95% CI: 1.135-3.008; p = 0.014) and the SLC28A3 rs885004 GG genotype (odds ratio: 2.034; 95% CI: 1.189-3.479; p = 0.010) were found to be associated with overall cardiac toxicity. The final predictive risk model consisting of clinical risk factors and SNPs was better than SNP alone (p = 0.006) or clinical risk factor alone (p = 0.065). Conclusion: On the basis of clinical factors, a prediction model with genetic susceptibility factors can better predict early-onset cardiac toxicity.
- Published
- 2022
- Full Text
- View/download PDF